A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 55-59

  Choi, Hye Jin ^a,b   Sohn, Joo Hyuk ^a,b   Lee, Chang Geol ^a,b   Shim, Hyo Sub ^b   Lee, Ik Jae ^a,b   Yang, Woo Ick ^b   Kwon, Ji Eun ^b   Kim, Se Kyu ^b   Park, Moo Suk ^b   Lee, Ju Hee ^b   Kim, Joo Hang ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Epidermal growth factor receptor (EGFR) inhibitor; Nimotuzumab; Non small cell lung cancer; Palliative radiotherapy; Phase I

Indexed keywords

NIMOTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; FEMALE; FEVER; FLUSHING; HAND FOOT SYNDROME; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INSOMNIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RASH; SIDE EFFECT; SKIN BIOPSY; SOUTH KOREA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPUBLIC OF KOREA;

EID: 78650189254     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.04.010     Document Type: Article

References (20)

1. Fairchild A., Harris K., Barnes E., Wong R., Lutz S., Bezjak A., Cheung P., Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008, 26:4001-4011.
2. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl. 4):2-8.
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
4. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., Li L.Y., Watkins C.L., Sellers M.V., Lowe E.S., Sun Y., Liao M.L., Osterlind K., Reck M., Armour A.A., Shepherd F.A., Lippman S.M., Douillard J.Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
5. Butts C.A., Bodkin D., Middleman E.L., Englund C.W., Ellison D., Alam Y., Kreisman H., Graze P., Maher J., Ross H.J., Ellis P.M., McNulty W., Kaplan E., Pautret V., Weber M.R., Shepherd F.A. Randomized phase II study of gemcitabine plus cisplatin or carboplatin with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007, 25:5777-5784.
6. Dent P., Reardon D.B., Park J.S., Bowers G., Logsdon C., Valerie K., Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999, 10:2493-2506.
7. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:1935-1940.
8. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
9. Crombet-Ramos T., Rak J., Perez R., Viloria-Petit A., Antiproliferative antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002, 101:567-575.
10. Akashi Y., Okamoto I., Iwasa T., Yoshida T., Suzuki M., Hatashita E., Yamada Y., Satoh T., Fukuoka M., Ono K., Nakagawa K. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008, 98:749-755.
11. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T., Averbuch S.D., Feyereislova A., Swaisland H., Rojo F., Albanell J., Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
12. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., Choi H.J., Kim Y.J., Shin S.J., Sohn J.H., Kim H., Kim J.H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007, 25:2528-2533.
13. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., Iznaga-Escobar N., Figueredo R., Koropatnick J., Renginfo E., Fernandez E., Alvarez D., Torres O., Ramos M., Leonard I., Perez R., Lage A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22:1646-1654.
14. Ramos T.C., Figueredo J., Catala M., Gonzalez S., Selva J.C., Cruz T.M., Toledo C., Silva S., Pestano Y., Ramos M., Leonard I., Torres O., Marinello P., Perez R., Lage A. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006, 5:375-379.
15. Allan D.G. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005, 10:760-761.
16. Thatcher N., Qian W., Clark P.I., Hopwood P., Sambrook R.J., Owens R., Stephens R.J., Girling D.J. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005, 23:8371-8379.
17. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
18. Yang C.H. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008, 60(Suppl. 2):S23-30.
19. Bebb G., Smith C., O'Rourke K., Brade A., Sherman I. Preliminary results of an escalating dose phase I/II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy. J Thoracic Oncol 2007, 2:s617.
20. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.